China’s NMPA logs 5,215 clinical trials in 2025, doubling since 2020

China’s drug regulator, the National Medical Products Administration (NMPA), reported a record year for clinical drug trials in 2025: 5,215 total trials. That is more than double the figure recorded in 2020, according to an NMPA report released on Monday.

What jumps out even faster is how much of that trial surge is aimed at genuinely new drugs. NMPA said 57.5% of the trials in the count were trials for new drugs. Put plainly: the pipeline is not just growing. It is tilting toward novel candidates at scale, and the pace is fast enough to trigger alarm bells beyond China.

The broader context matters because clinical trial registrations are basically a high-signal proxy for industrial momentum. They do not confirm which therapies will ultimately win approval or market traction. But when the number of registered clinical trials accelerates so sharply, it usually means sponsors are committing capital, recruiting sites and patients, and testing multiple hypotheses in parallel. That is how an ecosystem builds optionality. It is also how regulators and competitors spot the “where the money is going” directionally before outcomes are known.

According to the NMPA’s figures, the 2025 total of 5,215 clinical drug trials reflects that optionality expanding dramatically. The doubling versus 2020 is the kind of growth rate that tends to change how decision-makers allocate resources. For China-based companies, it can mean more standardized operations across trial sites, more competition for investigators, and faster learning loops from running many studies. For overseas sponsors, it can shift dealmaking and partnering decisions toward earlier-stage programs, since the volume of registered studies increases the universe of potential targets and collaboration opportunities.

There is also a regulatory layer to all this. China’s drug regulator releases these counts, which signals that the state is watching the pipeline as an indicator of innovation capacity and compliance. When a regulator highlights a record, it is not only reporting. It is framing. The subtext is that China’s biotech and pharma efforts are no longer a trickle. They are a manufacturing-scale activity with measurable throughput.

That matters because the SCMP summary flags US security concerns tied to the biotech surge. Even without details in the excerpt, the key business point for executives is that security concerns can quickly spill into procurement rules, collaboration approvals, investment reviews, and partnership terms. In other words, the issue is not only scientific. It is governance. Cross-border trial activity and data flows often sit at the intersection of public health goals and national risk frameworks, and a large trial pipeline can elevate scrutiny.

Boardrooms and investment committees should also think about what the “57.5% new-drug” composition implies for competitive dynamics. When more than half of trials target new drugs, it suggests sponsors are pursuing novelty, not only incremental line extensions. That typically increases the probability of breakthrough outcomes, but it also increases variability. A higher proportion of novel candidates can mean more failures, more protocol adjustments, and more expensive late-stage follow-through if early signals do not pan out. The trade-off is straightforward: more shots on goal, higher volatility in returns.

Finally, executives at biopharma, contract research organizations, and investors in life sciences should treat this as a pipeline signal with strategic consequences. China is recording a record 5,215 clinical drug trials in 2025, with 57.5% for new drugs, and the total is more than double 2020. When a jurisdiction’s trial engine scales this quickly, the rest of the market adapts. Competitors may accelerate their own registries, sponsors may adjust their geographic and regulatory strategies, and policymakers may tighten or redefine how cross-border biotech cooperation works. If US security concerns are indeed tied to the trial surge, that adds urgency for anyone planning multi-jurisdiction development programs, partnerships, or investment timelines.